Drugs / SYHX2011
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05274893 | Mar → Sep 2022 | breast cancer | CSPC Ouyi Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06354114 | Apr → Oct 2024 overdue | breast cancer | CSPC Ouyi Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07662811 | Jun 2026 → Dec 2027 expected | non-small cell lung carcinoma | Shanghai Chest Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYHX2011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05274893 ↗ |
| Route | Intravenous | “IV infusion” NCT05274893 ↗ |